<div id="readability-page-1"><p>Shares of AI data analytics firm Palantir Technologies (PLTR) are trending lower in pre-market trading amid reports that the UK is conducting a full review of its National Health Service (NHS) contract. The government is facing political pressure to consider using a break clause at the end of the initial term in early 2027. Britain is concerned about granting sensitive health data access to a U.S.-based firm, with lawmakers citing risks to patient confidentiality, public trust, and reliance on foreign suppliers.</p><h3>Introducing TipRanks MCP for Agents</h3><ul><li> Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. </li><li>Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.</li></ul> <p>A break clause is a contract provision that allows either party to end the agreement early under specified conditions. The 2023 contract, which involves building a platform to link NHS data, runs until early 2027, when the government will decide whether to renew or terminate it. Technology Minister Liz Kendall said Tuesday that the review will determine whether to extend the £330 million ($441 million) agreement for up to seven years or end it.</p> <h2><strong>Concerns Over Foreign Dependence</strong></h2> <p>Last week, a parliamentary committee urged ministers to activate the clause and end the contract, calling Palantir's role an &#34;unacceptable point of weakness.&#34; The committee also warned about the risks of relying heavily on a small number of U.S. tech firms, especially one with an expanding role in the public sector. At the same time, officials acknowledged benefits, including improved waiting list management, hospital operations, and discharge planning.</p> <p>The deal has also faced scrutiny because Palantir provides software to the U.S. military and immigration authorities. Additional concerns have been raised over the political views of its billionaire co-founder Peter Thiel, an early supporter of President Donald Trump.</p> <p>Campaigners and unions have raised concerns about how sensitive health data is handled. Last month, the <em>Financial Times</em> reported that NHS officials had proposed giving some external staff, including Palantir employees, broad administrative access to identifiable patient data in parts of the system.</p> <p>Meanwhile, Palantir says its software is designed to help the NHS improve both patient care and operational efficiency by making health data easier to use and analyze.</p> <h2><strong>Is Palantir a Good Stock to Buy?</strong></h2> <p>On TipRanks, PLTR stock has a Moderate Buy consensus rating based on 13 Buys, five Holds, and two Sell ratings. The average Palantir Technologies price target of $185.35 implies 35.8% upside potential from current levels. Year-to-date, PLTR shares have lost 23.2%.</p></div>

PLTR

PTIR

<p>Palantir (PLTR) shares declined as the UK reviews its £330 million NHS contract due to concerns over data security, foreign dependence, and political controversies. The government may use a break clause in 2027 to terminate or extend the deal. Despite parliamentary pressure citing risks to patient confidentiality, officials acknowledge operational benefits. Analysts maintain a Moderate Buy consensus with an average price target of $185.35.</p>

- Palantir Technologies (PLTR) shares are declining in pre-market trading due to a UK review of its NHS contract amid concerns over data security and reliance on a U.S. firm.  
- The £330 million contract is under scrutiny as lawmakers debate using a break clause to end it early, citing risks to patient confidentiality.  
- Despite concerns, some officials recognize benefits such as improved hospital operations, while Palantir maintains that its software enhances patient care and efficiency.

Palantir Stock (PLTR) Slides as UK Reopens NHS Deal Review